When treating adult patients with gBRCA-mutated HR+/HER2- or triple-negative locally advanced or metastatic breast cancer

*Capecitabine, eribulin, gemcitabine, or vinorelbine.
PFS was determined by blinded independent central review (BICR), according to RECIST, version 1.1. 

BRCA=breast cancer susceptibility gene; CI=confidence interval; gBRCA=germline breast cancer susceptibility gene; HER2-= human epidermal growth factor receptor 2 negative; HR=hazard ratio; HR+=hormone receptor-positive; RECIST=Response Evaluation Criteria in Solid Tumors.

  1. TALZENNA Summary of Product Characteristics.
  2. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and germline BRCA mutation. N Engl J Med. 2018;379(8)753-763.
  3. Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018;29:1939-1947.
  4. Hurvitz SA, Gonçalvez A, Rugo HS, et al. Talazoparib, an oral poly(ADP-ribose) polymerase inhibitor for patients with locally advanced/metastatic breast cancer and a germline BRCA mutation: detailed safety analyses from the randomized, multinational, phase 3 EMBRACA trial. Poster presented at: 36th Annual Miami Breast Cancer Conference; March 7-10, 2019; Miami, FL. Poster 761.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of full SmPC for how to report adverse reactions.